Innoviva INVA
NASDAQ INVA
$21.33 -0.02 (-0.09%)
As of: Sep 4, 2026 · 3:59 PM EDT

Innoviva (INVA) Total Non-Current Liabilities (2013 - 2026)

Innoviva's (INVA) quarterly Total Non-Current Liabilities came in at -$68.9 million in Q1 2026, down 494.3% YoY from $17.5 million in Q1 2025, and down 21.28% on a QoQ basis from -$56.8 million in Q4 2025.

Analysis

Innoviva (INVA) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends

Innoviva (INVA) has 14 years of Total Non-Current Liabilities data on file, last reported at -$68.9 million in Q1 2026.

  • Quarterly Total Non-Current Liabilities fell 494.3% year-over-year to -$68.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.9 million (down 494.3% YoY) and the FY2025 annual result came in at -$56.8 million, up 11.33% from the prior year.
  • Total Non-Current Liabilities eased to -$68.9 million in Q1 2026, from -$56.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $103.3 million in Q3 2023 to a low of -$71.5 million in Q2 2024.
  • A 5-year average of -$11.1 million and a median of -$55.0 million in 2025 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 20050.0% — and 2026, when it sank 494.3%.
  • Tracing INVA's Total Non-Current Liabilities over 5 years: stood at $40.3 million in 2022, then jumped by 156.24% to $103.3 million in 2023, then tumbled by 162.05% to -$64.1 million in 2024, then advanced by 11.33% to -$56.8 million in 2025, then dropped by 21.28% to -$68.9 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at -$68.9 million (Q1 2026), -$56.8 million (Q4 2025), and $45.2 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 3.92 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 1.53 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.88 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 4.20 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.32 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.17 Bn
10 Innoviva 1.56 Bn 984.81 Mn 90.62 Mn -67.18 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -67.18 Mn
Mar 31, 2026 -68.90 Mn
Dec 31, 2025 -65.99 Mn
Sep 30, 2025 45.15 Mn
Jun 30, 2025 -59.92 Mn
Mar 31, 2025 -61.81 Mn
Dec 31, 2024 -64.08 Mn
Sep 30, 2024 31.01 Mn
Jun 30, 2024 -71.47 Mn
Mar 31, 2024 -69.89 Mn
Dec 31, 2023 103.26 Mn
Sep 30, 2023 103.26 Mn
Jun 30, 2023 -67.88 Mn
Mar 31, 2023 -66.03 Mn
Dec 31, 2022 40.30 Mn
Sep 30, 2022 40.30 Mn
Dec 31, 2021 200,000.00
Sep 30, 2021 13.66 Mn
Jun 30, 2021 395.36 Mn
Mar 31, 2021 391.53 Mn